FDA Fast Tracks Psychedelic Treatments for Mental Health Concerns
The FDA is expediting pathways for the development of psychedelic therapies for serious mental illnesses, including treatment-resistant depression and PTSD. This strategic initiative, initiated by an executive order, signals increased federal support and potential contract opportunities for pharmaceutical companies and clinical research organizations.